Anti-doping Policies: Choosing Between Imperfections

Chapter
Part of the International Library of Ethics, Law, and the New Medicine book series (LIME, volume 52)

Abstract

In this chapter we suggest an alternative way of dealing with the problem of doping in sports. We find that today’s anti-doping policies are excessive, mostly driven by ideology and political convenience, ethically problematic, insufficiently effective, costly, and are possibly leading to more harm to society than they prevent. Anti-doping cannot achieve its declared objective (eradication of doping) since it cannot overcome the strong pressure towards winning at all cost and the limited effectiveness of surveillance. We think that the discussions on doping and anti-doping should not ignore the imperfect practical outcomes of current anti-doping policies, in elite, amateur and outside sports. Today’s anti-doping is not a solution, but an increasingly costly imperfection. We do not claim to know a way to an ultimate solution, simply because none exists, but we propose to consider a pragmatic utilitarian alternative respecting public health and ethical principles. We do this by drawing parallels between current anti-doping efforts and the ‘war on drugs’. Instead of an increasingly repressive anti-doping policy based on zero-tolerance with negative side effects, we propose to discuss another imperfection, one that might come with a reduced cost to the individual and society as compared to today’s imperfection, and that is based on regulation and harm minimisation.

Keywords

Organize Crime Psychotropic Drug Elite Athlete International Olympic Committee Elite Sport 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aitken, C., C. Delalande, and K. Stanton. 2002. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug and Alcohol Dependence 65(3): 303–308.CrossRefGoogle Scholar
  2. Amos, A. 2008. Anti-doping policy: Rationale or rationalisation. PhD thesis. University Library, Sydney.Google Scholar
  3. Banfi, G. 2011. Limits and pitfalls of athlete’s biological passport. Clinical Chemistry and Laboratory Medicine 49(9): 1417–1421.CrossRefGoogle Scholar
  4. Buss, D.M. 2001. Human nature and culture: an evolutionary psychological perspective.Journal of Personality 69(6): 955–978.Google Scholar
  5. Cakic, V. 2009. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology.” Journal of Medical Ethics 35(10): 611–615.Google Scholar
  6. Campos, D.R., M. Yonamine, and R. de Moraes Moreau. 2003. Marijuana as doping in sports. Sports Medicine (Auckland, N.Z.) 33(6): 395–399.CrossRefGoogle Scholar
  7. Carlsohn, A., M. Cassel, K. Linné, and F. Mayer. 2011. How much is too much? A case report of nutritional supplement use of a high-performance athlete. British Journal of Nutrition 105(12): 1724–1728.CrossRefGoogle Scholar
  8. Christiansen, A.V. 2011. Bodily violations testing citizens training recreationally in gyms. In Doping and anti-doping policy in sport, eds. M. McNamee and V. Moller. Andover: Routledge.Google Scholar
  9. Cole, C., L. Jones, J. McVeigh, A. Kicman, Q. Syed, and M. Bellis. 2010. Adulterants in illicit drugs: A review of empirical evidence. Drug Testing and Analysis 3(2): 89–96.CrossRefGoogle Scholar
  10. Currell, K., D.R. Moore, and P. Peeling. 2012. A–Z of nutritional supplements: Dietary supplements, sports nutrition foods and ergogenic aids for health and performance–Part 28. British Journal of Sports Medicine 46: 75–76.CrossRefGoogle Scholar
  11. D’Angelo, C., and C. Tamburrini. 2010. Addict to win? A different approach to doping. Journal of Medical Ethics 36(11): 700–707.CrossRefGoogle Scholar
  12. de Mondenard, J.-P. 2000. Historique et Évolution du Dopage. Annales De Toxicologie Analytique 12(1): 5–18.CrossRefGoogle Scholar
  13. de Mondenard, J.-P. 2011. Tour De France, 33 Vainqueurs Face Au Dopage, Entre 1947 Et 2010 – Historique de L’évolution du Dopage dans le Cyclisme. Paris: Hugo et Compagnie.Google Scholar
  14. Degenhardt, L., and W. Hall. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810): 55–70.CrossRefGoogle Scholar
  15. Degenhardt, L., W.T. Chiu, N. Sampson, and R.C. Kessler. 2008. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO world mental health surveys. PLoS Medicine 5(7): 1053–1067.CrossRefGoogle Scholar
  16. Donohue, J.J., B. Ewing, and D. Peloquin. 2011. Rethinking America’s illegal drug policy. Cambridge, MA: National Bureau of Economic Research.CrossRefGoogle Scholar
  17. EMCDDA. 2010. Harm reduction: Evidence, impacts and challenges. Luxembourg: Publications Office of the European Union.Google Scholar
  18. Fincoeur, B. 2009. Lutte Antidopage et Cyclisme à Deux Vitesses: Évolution du Rapport au Dopage chez les Cyclistes Belges depuis l’Affaire Festina. Revue Internationale De Criminologie Et De Police Technique Et Scientifique 3(9): 207–220.Google Scholar
  19. Frederick, D.A., J. Lever, and L.A. Peplau. 2007. Interest in cosmetic surgery and image: Views of men and women the lifespan. Plastic and Reconstructive Surgery 120(5): 1407–1415.CrossRefGoogle Scholar
  20. Garland, D. 2008. On the concept of moral panic. Crime, Media, Culture 4(1): 9–30.CrossRefGoogle Scholar
  21. GCDP. 2011. Report of the global commission on drug policy. www.Globalcommissionondrugs.org.
  22. Jelsma, M. 2003. Drugs in the UN system: The unwritten history of the 1998 United Nations General Assembly special session on drugs. The International Journal on Drug Policy 14(2): 181–195.CrossRefGoogle Scholar
  23. Jones, L., L. Pickering, H. Sumnall, J. McVeigh, and M.A. Bellis. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. The International Journal on Drug Policy 21(5): 335–342.CrossRefGoogle Scholar
  24. Kanayama, G., J.I. Hudson, and H.G. Pope. 2010. Illicit anabolic-androgenic steroid use. Hormones and Behavior 58(1): 111–121.CrossRefGoogle Scholar
  25. Kayser, B., and A. Smith. 2008. Globalisation of anti-doping: The reverse side of the medal. British Medical Journal (Clinical Research Edition) 337: a584.CrossRefGoogle Scholar
  26. Kayser, B., A. Mauron, and A. Miah. 2005. Viewpoint: Legalisation of performance-enhancing drugs. Lancet 366(Suppl 1): S21.CrossRefGoogle Scholar
  27. Kayser, B., A. Mauron, and A. Miah. 2007. Current anti-doping policy: A critical appraisal. BMC Medical Ethics 8: 2.CrossRefGoogle Scholar
  28. Kohler, M., A. Thomas, H. Geyer, M. Petrou, W. Schänzer, and M. Thevis. 2010. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne doping control laboratory 2009. Drug Testing and Analysis 2(11–12): 533–537.CrossRefGoogle Scholar
  29. Kraska, P.B., C.R. Bussard, and J.J. Brent. 2010. Trafficking in bodily perfection: Examining the late-modern steroid marketplace and its criminalization. Justice Quarterly 27(2): 159–185.CrossRefGoogle Scholar
  30. Larance, B., L. Degenhardt, J. Copeland, and P. Dillon. 2008. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug and Alcohol Review 27(6): 679–686.CrossRefGoogle Scholar
  31. Lentillon-Kaestner, V., and F. Ohl. 2011. Can we measure accurately the prevalence of doping? Scandinavian Journal of Medicine & Science in Sports 21(6): e132–e142.CrossRefGoogle Scholar
  32. Lentillon-Kaestner, V., M. S. Hagger, and S. Hardcastle. 2011. Health and doping in elite-level cycling. Scandinavian Journal of Medicine & Science in Sports. Health and Doping in Elite-Level Cycling (March 10): e-pub ahead of print.Google Scholar
  33. Lippi, G., and M. Plebani. 2011. Athlete’s biological passport: To test or not to test? Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 49(9): 1393–1395.Google Scholar
  34. Loland, S., and H. Hoppeler. 2011. Justifying anti-doping: The fair opportunity principle and the biology of performance enhancement. European Journal of Sport Science 12: 347–353.CrossRefGoogle Scholar
  35. McDowall, J.A. 2007. Supplement use by young athletes. Journal of Sports Science and Medicine 6(3): 337–342.Google Scholar
  36. McNamee, M.J., and L. Tarasti. 2010. Juridical and ethical peculiarities in doping policy. Journal of Medical Ethics 36(3): 165–169.CrossRefGoogle Scholar
  37. McVeigh, J., and C. Beynon. 2003. New challenges for agency based syringe exchange schemes: Analysis of 11 years of data (1991–2001) in Merseyside and Cheshire, United Kingdom. The International Journal on Drug Policy 14(5–6): 399–405.CrossRefGoogle Scholar
  38. Melnik, B.C. 2009. Androgen abuse in the community. Current Opinion in Endocrinology, Diabetes, and Obesity 16(3): 218–223.CrossRefGoogle Scholar
  39. Mendoza, J. 2002. The war on drugs in sport: A perspective from the front-line. Clinical Journal of Sport Medicine 12(4): 254–258.CrossRefGoogle Scholar
  40. Nature. 2007. A sporting chance. 448(7153): 512.Google Scholar
  41. Parkinson, A.B., and N.A. Evans. 2006. Anabolic androgenic steroids: A survey of 500 users. Medicine and Science in Sports and Exercise 38(4): 644–651.CrossRefGoogle Scholar
  42. Perneger, T. 2010. Speed trends of major cycling races: Does slower mean cleaner? International Journal of Sports Medicine 31(04): 261–264.CrossRefGoogle Scholar
  43. Petróczi, A. 2007. Attitudes and doping: A structural equation analysis of the relationship between Athletes’ attitudes, sport orientation and doping behaviour. Substance Abuse Treatment, Prevention, and Policy 2: 34.CrossRefGoogle Scholar
  44. Petróczi, A., and T. Nepusz. 2011. Methodological considerations regarding response bias effect in substance use research: Is correlation between the measured variables sufficient? Substance Abuse Treatment, Prevention, and Policy 6(1): 1.CrossRefGoogle Scholar
  45. Petróczi, A., G. Taylor, and D.P. Naughton. 2011a. Mission impossible? Regulatory and enforcement issues to ensure safety of dietary supplements. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 49(2): 393–402.CrossRefGoogle Scholar
  46. Petróczi, A., J. Mazanov, and D.P. Naughton. 2011b. Inside athletes’ minds: Preliminary results from a pilot study on mental representation of doping and potential implications for anti-doping. Substance Abuse Treatment, Prevention, and Policy 6: 10.CrossRefGoogle Scholar
  47. Pitsch, W. 2009. ‘The science of doping’ revisited: Fallacies of the current anti-doping regime. European Journal of Sport Science 9(2): 87–95.CrossRefGoogle Scholar
  48. Pitsch, W., and E. Emrich. 2011. The frequency of doping in elite sport: Results of a replication study. International Review for the Sociology of Sport (August 23). E-pub before print.Google Scholar
  49. Room, R., and P. Reuter. 2012. How well do international drug conventions protect public health? Lancet 379(9810): 84–91.CrossRefGoogle Scholar
  50. Sanchis-Gomar, F., V.E. Martinez-Bello, M.-C. Gomez-Cabrera, and J. Viña. 2011. Current limitations of the athlete’s biological passport use in sports. Clinical Chemistry and Laboratory Medicine 49(9): 1413–1415.CrossRefGoogle Scholar
  51. Saugy, M., L. Avois, C. Saudan, N. Robinson, C. Giroud, P. Mangin, and J. Dvorak. 2006. Cannabis and sport. British Journal of Sports Medicine 40(Suppl 1): i13–i15.CrossRefGoogle Scholar
  52. Schweizerische Eidgenössische Kommission für Drogenfragen (SEKD). 2006. Von Der Politik Der Illegalen Drogen Zur Politik Der Psychoaktiven Substanzen. Bern: Huber.Google Scholar
  53. Smith, M.E., and M.J. Farah. 2011. Are prescription stimulants ‘smart pills’? the epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 137(5): 717–741.CrossRefGoogle Scholar
  54. Sottas, P.E., N. Robinson, G. Fischetto, G. Dolle, J.M. Alonso, and M. Saugy. 2011. Prevalence of blood doping in samples collected from elite track and field athletes. Clinical Chemistry 57(5): 762–769.CrossRefGoogle Scholar
  55. Striegel, H., P. Simon, S. Frisch, K. Roecker, K. Dietz, H.-H. Dickhuth, and R. Ulrich. 2006. Anabolic ergogenic substance users in fitness-sports: A distinct group supported by the health care system. Drug and Alcohol Dependence 81(1): 11–19.CrossRefGoogle Scholar
  56. Striegel, H., R. Ulrich, and P. Simon. 2010. Randomized response estimates for doping and illicit drug use in elite athletes. Drug and Alcohol Dependence 106(2–3): 230–232.CrossRefGoogle Scholar
  57. Sullivan, R.J., and E.H. Hagen. 2002. Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction 97(4): 389–400.CrossRefGoogle Scholar
  58. Teter, C.J., S.E. McCabe, K. LaGrange, J.A. Cranford, and C.J. Boyd. 2006. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 26(10): 1501–1510.CrossRefGoogle Scholar
  59. WADA. 2009. World anti-doping code. www.wada-ama.org.
  60. WADA. 2012. International standard of testing. www.wada-ama.org.
  61. Wiesing, U. 2011. Should performance-enhancing drugs in sport be legalized under medical supervision? Sports Medicine (Auckland, N.Z.) 41(2): 167–176.CrossRefGoogle Scholar
  62. Wood, E., D. Werb, B. Marshall, J. Montaner, and T. Kerr. 2009. The war on drugs: A devastating public-policy disaster. Lancet 373(9668): 989–990.CrossRefGoogle Scholar
  63. Yesalis, C.E., and M.S. Bahrke. 2002. History of doping in sport. In Performance-enhancing substances in sport and exercise, ed. Charles E. Yesalis and Michael S. Bahrke. Champaign: Human Kinetics.Google Scholar
  64. Zorzoli, M. 2011. The athlete biological passport from the perspective of an anti-doping organization. Clinical Chemistry and Laboratory Medicine 49(9): 1423–1425.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Institute of Movement Sciences and Sports Medicine, Faculty of MedicineUniversity of GenevaGenevaSwitzerland
  2. 2.Unit for Dependency in Primary Care, Department of Community Health and Primary CareUniversity Hospitals of GenevaGenevaSwitzerland

Personalised recommendations